SCTX
スクライブ・セラピューティクス
SCTX
スクライブ・セラピューティクス
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR tech
Scribe Therapeutics is a Phase 1 clinical-stage biopharma developing in vivo CRISPR gene editing for disease prevention, targeting atherosclerotic cardiovascular disease. SCTX's lead candidate, STX-11